Traws Pharma
TRAW
19 hedge funds and large institutions have $3.98M invested in Traws Pharma in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
11.17% more ownership
Funds ownership: 23.27% → 34.44% (+11%)
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
61% less capital invested
Capital invested by funds: $10.2M → $3.98M (-$6.26M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.72M |
| 2 |
PA
Perceptive Advisors
New York
|
+$1.34M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$520K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$70.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$65.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$364K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$333K |
| 3 |
Renaissance Technologies
New York
|
-$89.3K |
| 4 |
Morgan Stanley
New York
|
-$78K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$10.3K |
TRAW Hedge Fund Activity: Q1 2025 in Review
19 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2025, worth a combined $3.98M — down 61% from $10.2M a quarter earlier.
Fund positioning in TRAW was balanced in Q1 2025: 3 funds opened new positions, 3 closed out, 8 added to existing stakes and 4 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $1.72M. The largest seller was Ikarian Capital, cutting an estimated $364K.
- 19 institutional investors held Traws Pharma (TRAW) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $3.98M of Traws Pharma stock for Q1 2025, down 61% quarter-over-quarter.
- 3 funds opened new Traws Pharma positions in Q1 2025 and 3 closed out, a net change of 0 holders.
- The largest Traws Pharma buyer in Q1 2025 was Adage Capital Partners, an estimated $1.72M added.
- The largest Traws Pharma seller in Q1 2025 was Ikarian Capital, an estimated $364K sold.
Based on aggregated 13F filings for Q1 2025.